Squarepoint
KDNY

Squarepoint’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Squarepoint’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-23,670
Closed -$465K – 3733
2022
Q3 		$465K Buy
23,670
+3,532
+18% +$70.8K ﹤0.01% 2239
2022
Q2 		$352K Buy
+20,138
New +$316K ﹤0.01% 2200
2022
Q1 		– Sell
-10,878
Closed -$177K – 3745
2021
Q4 		$177K Buy
+10,878
New +$155K ﹤0.01% 2755
2021
Q2 		– Sell
-23,954
Closed -$372K – 3863
2021
Q1 		$372K Buy
+23,954
New +$391K ﹤0.01% 2248
2020
Q1 		– Sell
-8,605
Closed -$51K – 2702
2019
Q4 		$51K Buy
+8,605
New +$46.8K ﹤0.01% 2392
2019
Q3 		– Sell
-17,558
Closed -$135K – 2764
2019
Q2 		$135K Buy
17,558
+14,158
+416% +$216K ﹤0.01% 2181
2019
Q1 		$68K Buy
+3,400
New +$59.3K ﹤0.01% 2063
2018
Q1 		– Sell
-5,395
Closed -$202K – 2273
2017
Q4 		$202K Buy
+5,395
New +$236K ﹤0.01% 1793

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Squarepoint's KDNY Position: Q4 2022 in Review

Squarepoint sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q4 2022, closing a stake of 23,670 shares — an estimated $465K sold.

Squarepoint first reported a position in KDNY in Q4 2017 and held it in 8 quarters. The position peaked at $465K in Q3 2022. 155 funds tracked by Wall St. Rank hold KDNY as of Q4 2022.

  • Squarepoint reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Squarepoint sold 23,670 Chinook Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $465K.
  • Squarepoint first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2017 and held it in 8 quarters.
  • Squarepoint's Chinook Therapeutics, Inc. Common Stock position peaked at $465K in Q3 2022.
  • 155 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Squarepoint's 13F filing for Q4 2022, filed 14 Feb 2023.